Clinical Research Studies
The DeLIVER programme is running 3 clinical research studies (DELPHI, SELINA and PEARL) that aim to provide a better understanding on why changes within the liver (and in case of DELPHI also the bile ducts and pancreas) can lead to cancer and identify markers that detect liver cancer at the earliest stages when curative therapies may be applied. The clinical research studies recruit patients over the age of 18 years with liver conditions and/or liver cancer from NHS sites in the UK.
The DELPHI study is comparing the characteristics of immune cells found in Hepatocellular Carcinoma (HCC or liver cancer) and other cancer types to cells collected from individuals with no cancer. Cells are collected from cancer/non-cancer tissue using FNA (Fine-needle aspiration) or from blood, urine and bile. The aim of the study is to identify changes to the immune system that may be present in cancer but not in non-cancer patients and therefore may have the potential to either indicate the early development of cancer or could flag that an individual could be at risk of developing cancer.